We observed in this large cohort study of patients with mild to severe CKD i) that higher apoA-IV concentrations at baseline were associated with a lower odds for a history of cancer and ii) that during 6.5 years of follow-up higher apoA-IV concentrations were associated with a lower risk for incident cancer, particularly fatal cancer outcomes. The gene discussed is APOA4; the disease is cancer.